Clene Inc Stock Current Valuation
| CLNN Stock | USD 4.14 0.13 3.04% |
Valuation analysis of Clene Inc helps investors to measure Clene's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of the 22nd of March 2025, Enterprise Value Over EBITDA is likely to drop to -0.75. In addition to that, Enterprise Value Multiple is likely to drop to -0.75. Fundamental drivers impacting Clene's valuation include:
Overvalued
Today
Please note that Clene's price fluctuation is relatively risky at this time. Calculation of the real value of Clene Inc is based on 3 months time horizon. Increasing Clene's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Clene is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Clene Stock. However, Clene's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.14 | Real 3.85 | Target 45.17 | Hype 4.14 | Naive 4.28 |
The intrinsic value of Clene's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Clene's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Clene Inc helps investors to forecast how Clene stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Clene more accurately as focusing exclusively on Clene's fundamentals will not take into account other important factors: Clene Inc Company Current Valuation Analysis
Clene's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Clene Current Valuation | 42.79 M |
Most of Clene's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Clene Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Clene Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Clene is extremely important. It helps to project a fair market value of Clene Stock properly, considering its historical fundamentals such as Current Valuation. Since Clene's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Clene's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Clene's interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Clene Inc has a Current Valuation of 42.79 M. This is 99.7% lower than that of the Biotechnology sector and 99.08% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.74% higher than that of the company.
Clene Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Clene's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Clene could also be used in its relative valuation, which is a method of valuing Clene by comparing valuation metrics of similar companies.Clene is currently under evaluation in current valuation category among its peers.
Clene ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Clene's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Clene's managers, analysts, and investors.Environmental | Governance | Social |
Clene Fundamentals
| Return On Equity | -4.17 | ||||
| Return On Asset | -0.47 | ||||
| Operating Margin | (89.83) % | ||||
| Current Valuation | 42.79 M | ||||
| Shares Outstanding | 8.33 M | ||||
| Shares Owned By Insiders | 38.68 % | ||||
| Shares Owned By Institutions | 18.72 % | ||||
| Number Of Shares Shorted | 123.81 K | ||||
| Price To Earning | 4.09 X | ||||
| Price To Book | 7.83 X | ||||
| Price To Sales | 84.24 X | ||||
| Revenue | 654 K | ||||
| Gross Profit | 331 K | ||||
| EBITDA | (43.24 M) | ||||
| Net Income | (49.5 M) | ||||
| Cash And Equivalents | 16.23 M | ||||
| Cash Per Share | 0.22 X | ||||
| Total Debt | 32.16 M | ||||
| Current Ratio | 3.49 X | ||||
| Book Value Per Share | (0.60) X | ||||
| Cash Flow From Operations | (30.17 M) | ||||
| Short Ratio | 2.54 X | ||||
| Earnings Per Share | (5.14) X | ||||
| Target Price | 45.17 | ||||
| Number Of Employees | 82 | ||||
| Beta | 0.26 | ||||
| Market Capitalization | 35.47 M | ||||
| Total Asset | 52.34 M | ||||
| Retained Earnings | (242.72 M) | ||||
| Working Capital | 13.52 M | ||||
| Net Asset | 52.34 M |
About Clene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Clene Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Clene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Clene Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Clene Inc is a strong investment it is important to analyze Clene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Clene's future performance. For an informed investment choice regarding Clene Stock, refer to the following important reports: Check out Clene Piotroski F Score and Clene Altman Z Score analysis. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clene. If investors know Clene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.614 | Earnings Share (5.14) | Revenue Per Share | Quarterly Revenue Growth (0.19) | Return On Assets |
The market value of Clene Inc is measured differently than its book value, which is the value of Clene that is recorded on the company's balance sheet. Investors also form their own opinion of Clene's value that differs from its market value or its book value, called intrinsic value, which is Clene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clene's market value can be influenced by many factors that don't directly affect Clene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.